GSK4024484

Unknown / undisclosed

Phase 1Mechanism not established

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Malaria
NCT06171113 · GlaxoSmithKline
2023-12-11 – 2026-06-16 · Malaria, Falciparum
What this study did

Competitive landscape

This drug's own stage for Malaria: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
GSK4024484: this drugPhase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
Ganaplacide / LumefantrinePhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
CipargaminPhase 2Small moleculePfATP4not yet gradedNo reviewed efficacy summary in this indication
GSK3772701Phase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
INE963
Phase 1(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
GSK4425689
—(overall)
UndisclosedCircumsporozoite protein (CSP)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.